VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
August 26, 2026 — Drug discovery can begin with 5,000 to 10,000 compounds, narrow to approximately 250 entering preclinical development, around five reaching clinical trials and ultimately produce just one approved medicine—highlighting why identifying weak drug candidates earlier can be critical to pharmaceutical R&D.
VivoSim Labs, Inc. (NASDAQ: VIVS) is targeting that decision-making process with its NAMkind™ 3D human liver and intestinal tissue models, designed to introduce human-relevant toxicity information earlier in drug development. VivoSim says its standard liver toxicology service can screen up to 200 compounds at multiple concentrations in approximately 17 days, potentially helping researchers determine which candidates should advance, undergo further optimization or be discontinued.
The opportunity could position VivoSim beyond traditional laboratory testing as a potential decision-support platform for pharmaceutical R&D, helping drug developers evaluate safety risks before committing substantially more capital to clinical development. VivoSim has reported approximately 91% predictive accuracy for liver toxicity, while its VitroSense™ AI platform has reported up to 96% predictive accuracy for drug-induced diarrhea.
Commercialization is beginning to advance through initial China programs and APAC distribution relationships, while VivoSim has reiterated guidance for 500%+ fiscal 2027 revenue growth from its NAM-based contract research business. The company also recently reported approximately $10.1 million in cash, supported in part by a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) related to a previously divested drug program.
Alongside VivoSim Labs (NASDAQ: VIVS), investors are also watching Cre8 Enterprise Ltd. (NASDAQ: CRE), Volato Group, Inc. (NYSE: SOAR), YY Group Ltd (NASDAQ: YYGH) and CDT Environmental Technology Ltd (NASDAQ: CDTG), as actively traded small-cap stocks continue drawing market attention.
For investors, the developing VivoSim opportunity is increasingly straightforward: help pharmaceutical companies identify which drugs deserve additional development capital—and which do not—earlier in the process.
About VivoSim Labs
VivoSim Labs, Inc. (NASDAQ: VIVS) provides pharmaceutical and biotechnology companies with 3D human liver and intestinal tissue models for drug testing and toxicology using New Approach Methodologies (NAMs).
About The Street Reports
The Street Reports (TSR) a financial media platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
: 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology){kind=link}